The biotech, which has developed a technology for administering active ingredients by microemulsion, recalls on Tuesday that three of its products currently in development are effective in the treatment of irradiated populations. The Stock Exchange is of course sensitive to the message, against a backdrop of armed conflict in Ukraine.
Medesis wants to accelerate in anti-nuclear products, message received 5 out of 5 on the stock market | Photo credits: Medesys
This is the largest increase on Tuesday at the Paris Stock Exchange. Medesis Pharma jumped more than 60%, to 5 euros all round, in response to a press release highlighting the properties of three of its drugs specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident.
As at the time of the first concerns linked to the Covid pandemic and the screening solutions mentioned by certain French companies, which had led to a surge in their stock market price, the message is received five out of five by investors. The action climbed more than 70%, to more than 5 euros, while continuing to yield 20% of its value since the IPO a little over a year ago.
Administration by microemulsion
Medesis Pharma was created in 2003 and has developed a technology for the administration of active ingredients by microemulsion. It uses microdroplets embedded in lipids that have a diameter of 3 nanometers. Administered orally, these nanomicelles transported by HDL proteins are released directly into the cells. There is therefore no problem with the passage of cell membranes. The active ingredients act at very low doses, which limits toxicity.
The biotech is leading four projects. Two kinds of molecules are used to be encapsulated: negative ions (lithium and manganese) which are toxic at therapeutic doses and siRNAs (interfering RNAs) which target part of the gene of a virus or an abnormal gene. Encapsulated manganese is used against Covid-19 in the same way that the product is effective in cases of irradiation linked to nuclear accidents, in the runaway phase of the immune system.
From NI01 to NP02
It is this primary characteristic which is therefore highlighted this time, in the context of the risk of a nuclear accident linked to the armed conflict in Ukraine. The three drug candidates developed by Medesis were developed in collaboration with the French Atomic Energy Commission (CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Institute for Biomedical Research of the Armed Forces ( IRBA) for studies on irradiated animals. Each of these products is protected by an international patent. In detail, these are NI01, for the decorporation of plutonium, NU02, for the decorporation of cesium and NP02, in nanomanganeses, with a view to treating respiratory and digestive inflammations triggered by irradiation and leading to dead.
If the therapeutic activity has been demonstrated, an additional program remains necessary with pharmaceutical development to move to an industrial production stage and to set up a tolerance study on healthy volunteers to demonstrate safety before introducing the products. in state emergency stocks. Applications for funding have already been submitted by biotech to the French Defense Innovation Agency.